Science Explorer Back to mapMap
Discussion

Juvaris BioTherapeutics (United States)

Research works
29
fractional, all time
Citations
480
16.7 per fractional work
Top-10% rate
6.8%
all institutions 10.0%
Open access
31%
world 40%
International
5%
world 18%

Not ranked overall: Juvaris BioTherapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Juvaris BioTherapeutics (United States) work in?

In all years, 48% of research at Juvaris BioTherapeutics (United States) is in Life Sciences, 46% in Health Sciences. Its largest fields are Medicine (46%), Immunology and Microbiology (27%), Biochemistry, Genetics and Molecular Biology (18%). It does 2.3× the world's share of Life Sciences.

Life Sciences: 14 fractional works · 48.4% of its workImmunology and Microbiology: 8 fractional works · 26.9% of its workImmunology: 7 fractional works · 25.8% of its workVirology: 0 fractional works · 1.1% of its workBiochemistry, Genetics and Molecular Biology: 5 fractional works · 17.7% of its workMolecular Biology: 3 fractional works · 9.9% of its workCancer Research: 1 fractional works · 3.4% of its workBiotechnology: 0 fractional works · 1.1% of its workCell Biology: 0 fractional works · 1.1% of its workGenetics: 0 fractional works · 0.8% of its workBiochemistry: 0 fractional works · 0.6% of its workEndocrinology: 0 fractional works · 0.4% of its workMolecular Medicine: 0 fractional works · 0.4% of its workAgricultural and Biological Sciences: 1 fractional works · 2.4% of its workAnimal Science and Zoology: 0 fractional works · 1.5% of its workEcology, Evolution, Behavior and Systematics: 0 fractional works · 0.8% of its workSmaller subfields together: 0 fractional works · 0.0% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.4% of its workPharmaceutical Science: 0 fractional works · 1.4% of its workHealth Sciences: 13 fractional works · 46.3% of its workMedicine: 13 fractional works · 46.3% of its workEpidemiology: 5 fractional works · 18.2% of its workOncology: 3 fractional works · 9.9% of its workRadiology, Nuclear Medicine and Imaging: 2 fractional works · 7.2% of its workHepatology: 1 fractional works · 2.8% of its workInfectious Diseases: 0 fractional works · 1.6% of its workGenetics: 0 fractional works · 1.1% of its workInternal Medicine: 0 fractional works · 1.1% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.8% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.6% of its workEmergency Medicine: 0 fractional works · 0.6% of its workImmunology and Allergy: 0 fractional works · 0.6% of its workRehabilitation: 0 fractional works · 0.6% of its workFamily Practice: 0 fractional works · 0.4% of its workDermatology: 0 fractional works · 0.2% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.4% of its workSocial Sciences: 1 fractional works · 3.5% of its workSocial Sciences: 1 fractional works · 3.5% of its workSociology and Political Science: 1 fractional works · 3.5% of its workPhysical Sciences: 0 fractional works · 1.7% of its workEngineering: 0 fractional works · 1.1% of its workBiomedical Engineering: 0 fractional works · 1.1% of its workEnvironmental Science: 0 fractional works · 0.6% of its workEcology: 0 fractional works · 0.6% of its workALL ITS WORKJuvarisBioTherapeutics…29fractional works, all years
Life Sciences48%Physical Sciences2%Health Sciences46%Social Sciences3%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 8 fields, with their numbers
    1. Immunology and Microbiology826.9%
    2. Biochemistry, Genetics and Molecular Biology517.7%
    3. Agricultural and Biological Sciences12.4%
    4. Pharmacology, Toxicology and Pharmaceutics01.4%
    1. Medicine1346.3%
    1. Social Sciences13.5%
    1. Engineering01.1%
    2. Environmental Science00.6%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Juvaris BioTherapeutics (United States)?

Ranked on the quality score, Jeff Fairman, Marla J. Lay and Stella Chang lead among researchers whose main affiliation is Juvaris BioTherapeutics (United States).

  1. 1 Jeff Fairman United States · #1,432,330 worldwide 1.3k citations · 67 works
  2. 2 Marla J. Lay United States · #2,169,104 worldwide 997 citations · 25 works
  3. 3 Stella Chang United States · #2,714,999 worldwide 916 citations · 38 works
  4. 4 Jeffery Fairman United States · #4,435,329 worldwide 270 citations · 29 works
All ranked researchers at Juvaris BioTherapeutics (United States)

What are the most cited papers from Juvaris BioTherapeutics (United States)?

The most cited paper from Juvaris BioTherapeutics (United States) is "Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs" (Christopher R. Behrens et al., 2015), with 162 citations. Next come "CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia" (124) and "Processes for Constructing Homogeneous Antibody Drug Conjugates" (78).

Most cited papers
#PaperReleasedCitations
1 Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs Christopher R. Behrens et al. · Molecular Pharmaceutics Open access 22 Sep 2015 162
2 CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia Jeevisha Bajaj, Takaaki Konuma, Nikki K. Lytle et al. · Cancer Cell Open access 27 Oct 2016 124
3 Processes for Constructing Homogeneous Antibody Drug Conjugates David Y. Jackson · Organic Process Research & Development Open access 14 Apr 2016 78
4 Effect of a glucagon receptor antibody (REMD‐477) in type 1 diabetes: A randomized controlled trial Jeremy Pettus, Dominic N. Reeds, Tricia Santos Cavaiola et al. · Diabetes Obesity and Metabolism Open access 28 Dec 2017 68
5 Antitumor activity of an anti‐ CD 98 antibody Gregory M. Hayes, Lawrence Chinn, Joseph M. Cantor et al. · International Journal of Cancer Open access 29 Dec 2014 67
All 39 most cited papers, with filters and sorting

Which keywords describe research at Juvaris BioTherapeutics (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Epidemiology, Pathogenesis, Innate Immunity, Antigen Presentation, Cancer Immunotherapy, Dendritic Cells, Immunity and Antibodies.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 37 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 37 words, with their numbers
  1. Epidemiology6▲ 5.0×13 topics
  2. Innate Immunity4▲ 45×2 topics
  3. Pathogenesis4▲ 28×6 topics
  4. Antigen Presentation4▲ 154×2 topics
  5. Cancer Immunotherapy4▲ 106×2 topics
  6. Dendritic Cells4▲ 114×1 topic
  7. Immunity4▲ 39×1 topic
  8. Antibodies4▲ 141×2 topics
  9. Vaccines4▲ 176×2 topics
  10. Genomics3▲ 34×2 topics
  11. Virus3▲ 99×2 topics
  12. H1N13▲ 312×1 topic
  13. Influenza3▲ 236×1 topic
  14. Inflammation3▲ 4.2×6 topics
  15. Pattern Recognition Receptors3▲ 66×2 topics
  16. Immune Response2▲ 14×5 topics
  17. Monoclonal Antibodies2▲ 53×2 topics
  18. Therapeutic Antibodies2▲ 59×2 topics
  19. Toll-like Receptors2▲ 45×2 topics
  20. Cytokine-Mediated Link2▲ 102×1 topic
  21. Innate Antiviral Responses2▲ 102×1 topic
  22. Antibody Engineering2▲ 64×1 topic
  23. Fc Receptors2▲ 64×1 topic
  24. Chemotherapy2▲ 8.2×2 topics
  25. Angiogenesis2▲ 13×6 topics
  26. Antiviral Therapy2▲ 34×3 topics
  27. Global Burden1▲ 8.9×2 topics
  28. Liver Disease1▲ 35×2 topics
  29. Vaccine1▲ 12×5 topics
  30. Breast Cancer1▲ 17×1 topic
  31. HER21▲ 152×1 topic
  32. Hepatocellular Carcinoma1▲ 18×2 topics
  33. Chronic Hepatitis B1▲ 69×1 topic
  34. Citizenship Education1▲ 64×1 topic
  35. Hepatitis B Virus1▲ 69×1 topic
  36. Historical Thinking1▲ 142×1 topic
  37. Metastasis1▲ 10×2 topics

Which research topics does Juvaris BioTherapeutics (United States) publish most on?

By volume in 2022-now: CAR-T cell therapy research, Liver physiology and pathology, CRISPR and Genetic Engineering and Cell Adhesion Molecules Research.

  1. 1 CAR-T cell therapy research Oncology 0 works
  2. 2 Liver physiology and pathology Hepatology 0 works
  3. 3 CRISPR and Genetic Engineering Molecular Biology 0 works
  4. 4 Cell Adhesion Molecules Research Immunology and Allergy 0 works
  5. 5 Chemokine receptors and signaling Oncology 0 works
  6. 6 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  7. 7 Corneal Surgery and Treatments Radiology, Nuclear Medicine and Imaging 0 works
  8. 8 Wound Healing and Treatments Rehabilitation 0 works
  9. 9 Proteoglycans and glycosaminoglycans research Cell Biology 0 works
  10. 10 Medication Adherence and Compliance Family Practice 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available30.8%not open69.2%

World: 40% of research is openly available.

with international co-authors4.9%domestic only95.1%

World: 18% is written across borders.

How has Juvaris BioTherapeutics (United States)'s research output changed?

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Juvaris BioTherapeutics (United States) as a percentage of every work published that year, 0.0000011% in 2024.

still counting0.00010%0.00020%0.00030%Juvaris BioTherapeutics (United States)0.000017% in 2025200020102020

Fractional works of Juvaris BioTherapeutics (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Pleasanton

All research institutions in Pleasanton

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Juvaris BioTherapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.